Literature DB >> 29267660

Reclassification and treatment of odontogenic keratocysts: A cohort study.

Ophir Ribeiro-Júnior1, Alexandre Meireles Borba1, Carlos Augusto Ferreira Alves2, Marcia Maria de Gouveia2, Maria Cristina Zindel Deboni1, Maria da Graça Naclério-Homem1.   

Abstract

The odontogenic keratocyst (OKC) is a recurrent cyst that has been recently reclassified from an odontogenic tumor to an odontogenic cyst. The aim of the present study was to investigate its treatment and address issues related to its association with nevoid basal cell carcinoma syndrome (NBCCS). Lesions from the cohort of patients included in the present study consisted of 40 OKCs, of which 27 lesions were treated by enucleation (GE) and 13 underwent decompression (GD). Complementary treatment occurred in 38 (95%) lesions, of which 10 underwent isolated peripheral ostectomy (GO) and 28 underwent peripheral ostectomy combined with Carnoy's solution (GC). Thirteen lesions were associated with NBCCS (GS), while the others (n=27) were non-syndromic lesions (GnS). The recurrence-free periods (RFP) in the sample groups were compared using the Kaplan-Meier function and log-rank test at a significance level of 5% (p < 0.05) and were used to calculate the cumulative risk of recurrence (CRR) in each postoperative year. During the follow-up period, which had a mean of 43.5 months (range: 12-102 months), six (15%) recurrences were diagnosed. There was no significant difference among the RFP for the compared groups (p > 0.05) or increased CRR for the decompression (15.4%) over five years. Application of Carnoy's solution did not increase the efficacy of the peripheral ostectomy, but was related to a CRR of 0% for the syndromic lesions over five years. Therefore, 1) decompression did not increase the recurrence risk; 2) peripheral ostectomy demonstrated a similar efficacy as the combination with Carnoy's solution; 3) the association of NBCCS did not seem to significantly influence OKC recurrence; and 4) syndromic lesions seem to behave in the same manner as non-syndromic lesions when submitted to complementary treatments.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29267660     DOI: 10.1590/1807-3107bor-2017.vol31.0098

Source DB:  PubMed          Journal:  Braz Oral Res        ISSN: 1806-8324


  6 in total

Review 1.  Multidisciplinary approach to Gorlin-Goltz syndrome: from diagnosis to surgical treatment of jawbones.

Authors:  Francesco Spadari; Federica Pulicari; Matteo Pellegrini; Andrea Scribante; Umberto Garagiola
Journal:  Maxillofac Plast Reconstr Surg       Date:  2022-07-18

2.  Orthokeratinized versus parakeratinized odontogenic keratocyst: Our institutional experience.

Authors:  Jyoti Ravi; Vijay Wadhwan; Suhasini Palakshappa Gotur
Journal:  J Oral Maxillofac Pathol       Date:  2022-03-31

3.  A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome).

Authors:  B J A Verkouteren; B Cosgun; M G H C Reinders; P A W K Kessler; R J Vermeulen; M Klaassens; S Lambrechts; J R van Rheenen; M van Geel; M Vreeburg; K Mosterd
Journal:  Br J Dermatol       Date:  2021-11-08       Impact factor: 11.113

Review 4.  Decompression or Marsupialization; Which Conservative Treatment is Associated with Low Recurrence Rate in Keratocystic Odontogenic Tumors? A Systematic Review.

Authors:  Reza Tabrizi; Mohammad Reza Hosseini Kordkheili; Mohammad Jafarian; Farzad Aghdashi
Journal:  J Dent (Shiraz)       Date:  2019-09

5.  Radiolucent Lesions of the Jaws: An Attempted Demonstration of the Use of Co-Word Analysis to List Main Similar Pathologies.

Authors:  Andy Wai Kan Yeung
Journal:  Int J Environ Res Public Health       Date:  2022-02-09       Impact factor: 3.390

6.  Deep Learning-Based Microscopic Diagnosis of Odontogenic Keratocysts and Non-Keratocysts in Haematoxylin and Eosin-Stained Incisional Biopsies.

Authors:  Roopa S Rao; Divya B Shivanna; Kirti S Mahadevpur; Sinchana G Shivaramegowda; Spoorthi Prakash; Surendra Lakshminarayana; Shankargouda Patil
Journal:  Diagnostics (Basel)       Date:  2021-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.